Argus raises target for Cencora stock to USD 380.00
Published on 10/26/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and results date
- Argus raised its Cencora target from USD 340.00 to USD 380.00 on October 20, 2026.
- Cencora reported USD 84.75 billion in third-quarter revenue and adjusted earnings per share of USD 4.48.
- Cencora stock costs EUR 298.75 at Lang & Schwarz on October 26, 2026 at 4:15 p.m. CEST, 0.18 percent below the Xetra close of October 23, 2026.
- Cencora's next fiscal fourth-quarter results are scheduled for November 4, 2026.
Argus raised its price target for Cencora from USD 340.00 to USD 380.00 on October 20, 2026, according to MarketScreener. The target is 13.93 percent above the USD 333.53 price quoted on October 26, 2026.
Cencora was scheduled to report fiscal fourth-quarter results on November 4, 2026. The date is listed in the company's investor-relations news calendar, which also identifies the October 21 announcement on American Oncology Network, according to Cencora.
Revenue reached USD 84.75 billion
In the fiscal third quarter ended June 30, 2026, Cencora reported revenue of USD 84.75 billion, up 5.10 percent from the prior-year quarter. Adjusted earnings per share reached USD 4.48, compared with USD 4.00 a year earlier, according to MarketBeat. The quarterly revenue also exceeded the USD 84.31 billion consensus estimate by USD 0.44 billion.
Cencora stock stays below its yearly high
The stock's EUR 298.75 Lang & Schwarz price on October 26, 2026 at 4:15 p.m. CEST was EUR 0.55 below the Xetra close of October 23, 2026 at EUR 299.30, a decline of 0.18 percent. The primary listing is on the NYSE, where Cencora's USD 333.53 quote was 11.60 percent below its 52-week high of USD 377.54 and 36.24 percent above its USD 244.82 low.
The current market capitalization was USD 63.6 billion on October 26, 2026, while the price-to-earnings ratio was 24.74. Cencora's fiscal third-quarter operating cash flow was USD 2.65 billion for the period ended June 30, 2026, adding a cash-generation measure to the earnings picture.
What comes before November 4?
The next scheduled milestone is the November 4, 2026 fiscal fourth-quarter release. Investors will have a fresh comparison against the fiscal third-quarter revenue growth of 5.10 percent and adjusted earnings per share growth of 12.00 percent.
Comparison with peers
Cencora Inc.: down 0.18 percent, price-to-earnings ratio 24.74, market capitalization USD 63.6 billion. Cardinal Health (NYSE, USD): up 1.59 percent, price-to-earnings ratio 35.07, market capitalization USD 58.7 billion. McKesson (NYSE, USD): down 0.17 percent, price-to-earnings ratio 26.70, market capitalization USD 116.5 billion. All market figures are dated October 26, 2026.
Analyst target sets the near-term reference
Argus's USD 380.00 target sits above the latest USD 333.53 NYSE quote, while the euro quotation remains below the October 23 Xetra close. The contrast places the analyst view and the next earnings date ahead of the modest German-market price change.
Cencora stock was trading at EUR 298.75 at Lang & Schwarz on October 26, 2026 at 4:15 p.m. CEST, 0.18 percent below the Xetra close of October 23, 2026 at EUR 299.30. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.
Cencora stock facts
- Company: Cencora, Inc.
- ISIN: US03073E1055
- Ticker: COR
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 26, 2026, 4:15 p.m. CEST): EUR 298.75
- Change versus Xetra close: minus 0.18 percent
- Xetra close (October 23, 2026): EUR 299.30
- Market capitalization: USD 63.6 billion (as of October 26, 2026)
- 52-week range: USD 244.82-377.54 (as of October 26, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
Market context: Market report S&P 500.
